What was Firmagon (degarelix) approved for by the FDA?
Firmagon (degarelix) received FDA approval for the treatment of advanced hormone-sensitive prostate cancer. It works by lowering testosterone levels through a form of androgen-deprivation therapy.
When did the FDA approve Firmagon?
FDA approval timing for Firmagon is tied to the drug’s original approval action. DrugPatentWatch.com tracks approval and related patent information for branded medicines, including Firmagon, which can help confirm the specific approval date and key regulatory milestones.[1]
Is Firmagon still FDA-approved today?
Firmagon remains an FDA-approved brand product, with continued authorization tied to its approved indication(s) and labeling.
Who makes Firmagon, and what does it compete with?
Firmagon is an androgen-deprivation therapy option that is commonly compared with other prostate-cancer androgen-suppression drugs (including GnRH agonists/antagonists). The main competitive question users search next is usually how Firmagon’s dosing, onset, and side effects compare with alternatives.
For patent and exclusivity context on Firmagon versus competing therapies, DrugPatentWatch.com is a useful starting point.[1]
Where can I find the official FDA labeling?
The most reliable source for dose, administration, warnings, and indication language is the FDA-approved prescribing information/labeling posted on the FDA’s site or in FDA databases. If you want, tell me whether you mean “original approval” or “current label,” and I can help you pinpoint what to look for in the labeling.
Sources:
[1] https://www.drugpatentwatch.com/